A Study of Peginterferon Alfa-2a [PEGASYS] in Patients With Chronic Hepatitis B Who Are HBeAg Positive
Launched by HOFFMANN-LA ROCHE · Mar 11, 2010
Trial Information
Current as of May 11, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adult patients \>/=18 years of age
- • HBeAg positive chronic hepatitis B
- • Compensated liver disease
- Exclusion Criteria:
- • Patients who had previously received treatment of drugs with activity against HBV within 6 months prior to study start
- • Antiviral, anti-neoplastic or immunomodulatory treatment
- • Co-infection with active hepatitis A, hepatitis C, hepatitis D, or HIV
- • Evidence of decompensated liver disease
- • Chronic liver disease other than viral hepatitis
About Hoffmann La Roche
Hoffmann-La Roche, commonly known as Roche, is a global leader in biotechnology and pharmaceuticals, committed to advancing healthcare through innovative research and development. With a strong focus on oncology, immunology, infectious diseases, and central nervous system disorders, Roche leverages cutting-edge science to deliver transformative therapies and diagnostics. The company is dedicated to improving patient outcomes by conducting rigorous clinical trials and collaborating with healthcare professionals and organizations worldwide. Roche's unwavering commitment to precision medicine and personalized healthcare positions it at the forefront of the industry, driving progress in the quest for effective treatments and improved patient care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Shanghai, , China
Wuhan, , China
Beijing, , China
Guangzhou, , China
Beijing, , China
Xi'an, , China
Changchun, , China
Patients applied
Trial Officials
Clinical Trials
Study Director
Hoffmann-La Roche
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials